Search

Background: Hypersecretion of mucin in the airway epithelium is an important feature of allergic airway diseases. Of the 3 cysteinyl leukotrienes (CysLTs; LTC4 LTD4 and LTE4), only LTE4 is sufficiently stable to be detectable in extracellular fluids. However, LTE4 has received little attention because it binds poorly to the CysLT1 and CysLT2 receptors; therefore, little is known about the effects of LTE4 on mucous secretion. Recently, studies have focused on the P2Y12 receptor as a potential receptor for LTE4, because this receptor is required for LTE4-mediated pulmonary inflammation. In our previous study, we confirmed the expression of P2Y12 receptor in human airway epithelial cells. To clarify the roles of LTE4 in airway epithelial cells, we investigated mucus secretion by LTE4 in vitro., Methods: Confluent NCI-H292 cells were stimulated with LTE4 (0.01-1 μM) for 24 h. The release and production of MUC5AC protein, a gel-forming mucin, were evaluated with an enzyme-linked immunosorbent assay., Results: Western blot analysis revealed that NCI-H292 cells expressed P2Y12 receptor protein. LTE4 significantly induced the release of MUC5AC mucin in a dose-dependent manner. Th2 cytokines such as IL-4 (10 ng/mL) and IL-13 (10 ng/mL) accelerated the LTE4-induced release of MUC5AC protein. MRS2935, a P2Y12 receptor antagonist, partially inhibited the LTE4-induced release of MUC5AC protein in the airway. In contrast, MK571, a CysLT1 receptor antagonist, did not affect the release of MUC5AC protein elicited by LTE4., Conclusions: These results suggest that LTE4 may play some important roles in allergic mucus secretion partially via activation of P2Y12 receptor., (Copyright © 2014 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.)

Background: Extracellular nucleotides such as ATP and UTP are released from essentially all cells, and they interact with cell surface P2 receptors to produce a broad range of physiological responses. P2Y12 receptor is the major platelet receptor that mediates ADP-induced aggregation, P2Y12 receptor inhibitors such as clopidogrel and prasugrel inhibit platelet aggregation, and thus, they are used in the treatment and prevention of coronary artery disease. Recently, studies have focused on the P2Y12 receptor as a receptor for leukotriene E4 (LTE4), because this receptor is required for LTE4-mediated pulmonary inflammation. To establish the presence of P2Y12 receptor in human nasal mucosa, we investigated the expression and the localization of the P2Y12 receptor in human nasal mucosa., Methods: Human turbinates were obtained by turbinectomy from 12 patients with nasal obstruction refractory to medical therapy. The expression of P2Y12 receptor was evaluated by RT-PCR, western blotting, and immunohistochemical analysis., Results: RT-PCR analysis of total RNA extracted from human nasal turbinate, primary cultured human nasal epithelial cells and nasal vascular endothelial cells demonstrated the expression of P2Y12 receptor mRNA. A band of approximately 55 kDa was detected in human turbinates by western blot analysis using anti-P2Y12 receptor antibody. We could not find any differences between P2Y12 receptor levels in allergic and non-allergic nasal mucosa. An immunohistochemical study revealed that epithelial cells, submucosal glands and vascular endothelial cells showed intense immunoreactivity for the P2Y12 receptor., Conclusions: The results may have important clinical implications for understanding the role of P2Y12 receptor in upper airway diseases such as allergic rhinitis and non-allergic rhinitis.

Thromboxane A2 (TXA2) has been thought a potent mediator involved in allergic rhinitis, because TXA2 was recovered from the nasal lavage fluid of allergic rhinitis patients after allergen provocation and TXA2 receptor antagonists relief nasal allergic symptoms. In order to clarify the expression of TXA2 receptor in human nasal mucosa, we investigated TXA2 receptor mRNA expression and its protein localization by polymerase chain reaction (PCR) and immunohistochemistry, respectively. Human turbinates were obtained after turbinectomy from 10 patients with nasal obstruction refractory to medical therapy. RT-PCR analysis of total RNA from nasal mucosa demonstrated the expression of TXA2 receptor alpha mRNA. The immunohistochemical studies revealed that anti-TXA2 receptor alpha antibody labeled vascular smooth muscle cells, vascular endothelial cells, epithelial cells and submucosal glands in the nasal mucosa. The results may have an important clinical implication for understanding the role of TXA2 receptor on upper airway diseases such as allergic rhinitis and non-allergic rhinitis.

Glucocorticoids are known to be effective in the treatment of nasal polyps (NPs). To examine the mechanisms of their effect, we evaluated 1) the ability of glucocorticoids to induce the apoptosis of eosinophils and T lymphocytes in NPs, and 2) the ability of dexamethasone to down-regulate epithelial cell functions that relate to eosinophilic inflammation. In vitro and in vivo, glucocorticoids increased the apoptosis of both eosinophils and T lymphocytes in NPs. Dexamethasone inhibited the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) from both NP epithelial cells that were unstimulated and NP epithelial cells that were stimulated with interleukin-4 or tumor necrosis factor alpha. These results suggest that the clinical efficacy of glucocorticoids on NPs may be due to 1) induction of apoptosis in both eosinophils and T lymphocytes that infiltrate NPs, and 2) down-regulation of epithelial GM-CSF production, which prolongs eosinophil survival.

Objective: Mucins are high molecular weight glycoproteins which are normally expressed on the surface of a variety of epithelia. It is possible that shedding of such molecules from the epithelium could play a role in preventing bacterial colonization at the mucosal surface. Immunohistochemical and reverse transcriptase polymerase chain reaction(RT-PCR) analyses of human inferior turbinates have shown the existence of MUC1 mucin in nasal mucosa. However, the regulatory mechanisms of MUC1 mucin are poorly understood. In order to clarify the modulation of mucin gene expression, we developed a real-time semi-quantitative RT-PCR based on TaqMan fluorescence methodology to quantify MUC1 mRNA in primary cultured human nasal epithelial cells (HNECs)., Material and Methods: HNECs were stimulated with recombinant human tumor necrosis factor (TNF)-alpha (20 pg/ml to 20 ng/ml) for specified time periods (0, 12, 24 and 48 h) and MUC1 mRNA was determined by means of semi-quantitative RT-PCR., Results: Significant increases in MUC1 gene expression in HNECs were initially detected at 12 h, peaking at 24 h after stimulation. TNF-mediated MUCI mRNA expression at 24 h was significantly inhibited by co-incubation with human recombinant soluble TNF receptor., Conclusions: TNF-mediated MUC1 gene expression may contribute to the pathogenesis of human inflammatory upper airway disorders. Also, our mucin mRNA real-time PCR provides a quantitative method for investigating the regulation of mucin gene expression in both healthy and diseased samples.

In order to confirm the direct effect of glucocorticosteroids on epithelial intercellular adhesion molecule-1 (1CAM-1) expression, we examined ICAM-I expression on primary cultured human nasal epithelial cells (HNECS) at both protein and mRNA levels. HNECs were stimulated with recombinant human TNF-α (20pg mL-20ng mL) for specified time periods (0, 12, 24, and 48h) and ICAM-I mRNA and the soluble ICAM-I (sICAM-I) concentrations were measured by quantitative RT-PCR and ELISA, respectively. We also evaluated surface expression of ICAM-I by flow cytometry 48h after stimulation and determined the effect of dexamethasone (DEX) on TNF-α induced ICAM-I expression. Significant increases in ICAM-I gene expression in HNECs were initially detected at 24h. peaking at 48h after the stimulation. The TNF-mediated ICAM-I mRNA and ICAM-I surface expression at 48h was significantly inhibited by co incubation with human recombinant soluble TNF receptor 1. Similarly, TNF-α-induced release sICAM-I occurred in a time- and concentration-dependent manner. DEX 10-6 attenuated the TNF-α-induced ICAM-I expression at mRNA and protein levels. Our finding suggests a potential role for topical steroids in allergic rhinitis in suppressing inflammatory reactions in the nasal mucosa by regulating ICAM-I expression on nasal epithelium. [ABSTRACT FROM AUTHOR]